NCT06785922Enrolling by invitation
Differences in Gastric Microbiota in Patients Who Were Infected Between CagA Positive and Negative Helicobacter Pylori
Source: ClinicalTrials.gov · Last updated 21 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to study the differences in gastric microbiota (Diversity index) between patients who were infected with CagA-positive Helicobacter pylori and CagA-negative Helicobacter pylori. The main question it aims to answer are: The effect of Helicobacter pylori typing (CagA status) on gastric microbiota, what is the different? Patients indicated for EGD at Siriraj Endoscopic Center will undergo a Helicobacter pylori test (Rapid urease test) If the result is positive, a stomach biopsy for gastric microbiota testing and CagA antibody testing will be conducted. Then, the patients will be divided into two groups: CagA-positive Helicobacter pylori and CagA-negative Helicobacter pylori. To compare the differences in gastric microbiota in terms of species and biodiversity, as well as endoscopic results, etc.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- First submitted
- 15 Jan 2025
- Start date
- 12 Jan 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Mahidol University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06785922
What you commit to
- Study type: Interventional
- Planned participants: 64
- From 12 Jan 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving medications that affect the gastric microbiota include Antibiotics, probiotics, or bismuth within 4 weeks, PPI within 2 weeks, NSAIDs or Metformin within 2 weeks
Other illness
- Severe comorbidities: poorly controlled DM, ESRD, decompensated cirrhosis, Malignancy
- History of cholecystectomy or proximal small bowel surgery
Other
- BMI ≤ 23 kg/m2
Who the study is looking for
- Patients aged over 18 with an indication for EGD
- Helicobacter pylori infection (Rapid urease test positive)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of internal medicine siriraj hospital, Mahidol university Coordinator of this site? Confirm its status | Bangkok Noi | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.